ENDRA Life Sciences Inc. (NDRA) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $5.14. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Valuation: NDRA trades at a trailing Price-to-Earnings (P/E) of -0.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Net income is $7M (loss), growing at +16.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $492,352 against $2M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 1.29 (adequate). Debt-to-assets is 12.8%. Total assets: $4M.
Analyst outlook: 4 / 4 analysts rate NDRA as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 80/100 (Pass), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
